Our Aims
OUR AIMS
Our main objective is to demonstrate that vaccine if initiated at the time of local treatment will reduce the risk of subsequent HPV infection in women with high-grade precancer.
If this study demonstrates benefits from vaccination, this vaccine may be offered to all women having local treatment. If proven of value, vaccination may prevent subsequent cervical, vulvar and vaginal precancerous disease and anogenital warts in this high-risk population.
In England alone, 3.6 million women aged between 25 and 64 attended for screening in 2013-14, one in ten had abnormal results and over 23800 local treatments were carried out. The majority of treated women are of a young age. The efficacy of the HPV vaccines is very high in women who have not been previously exposed to HPV. Although the vaccines do not appear to help clearance of ongoing infections at the time of the vaccine, there may be a role for women having cervical treatment, a particularly high-risk group susceptible to new and recurrent HPV infection and development of precancerous lesions. The literature is unclear and a clinical trial is needed.
